<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719768</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-19648</org_study_id>
    <secondary_id>W1239387</secondary_id>
    <nct_id>NCT03719768</nct_id>
  </id_info>
  <brief_title>Avelumab With Radiotherapy in Patients With Leptomeningeal Disease</brief_title>
  <official_title>Phase IB Study of Avelumab With Radiotherapy in Patients With Leptomeningeal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to find a safe dose of the combination of Avelumab and Whole Brain Radiotherapy&#xD;
      (WBRT) in patients with Leptomeningeal Disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Dose Limiting Toxicity (DLT) measured by number of subjects with adverse events (AEs)</measure>
    <time_frame>End of treatment (3 months)</time_frame>
    <description>Adverse events will only include those that are determined to be related to study drug.&#xD;
A DLT will be defined as any one of the following adverse events occurring within 28 days from first dose of Avelumab. Central Nervous System (CNS) toxicities: Any grade 3 or higher central nervous adverse events, including but not limited to cerebral hemorrhage and new-onset neurologic deficit. Non-CNS toxicities: Any grade 3 or higher nonhematologic AE with the exception of alopecia and fatigue - Grade &gt; 3 nausea, vomiting, or diarrhea despite maximal medical therapy - Grade &gt; 3 laboratory value if 1)medical intervention is required to treat the patient or 2) the abnormality leads to hospitalization â€¢ Any grade 3 or 4 event that does not improve within 6 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of T Cells</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>The number of T cells in the cerebrospinal fluid (CSF) and the CSF cytokine activation profile in the CSF (relative to serum) measured before and after Avelumab administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation Status of T Cells</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>The activation status of T cells in the cerebrospinal fluid (CSF) and the CSF cytokine activation profile in the CSF (relative to serum) measured before and after Avelumab administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptomeningeal Disease (LMDz)/CNS Response Rate and Systemic Response Rate</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Any solid brain metastases associated with LMDz will be assessed with Response Assessment in Neuro-Oncology (RANO)-Brain Metastases (BM) criteria. Responses in the rest of the body will be measured using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall Survival (OS) Rate at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>OS, utilizing 95% confidence interval (95%CI).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Leptomeningeal Metastases</condition>
  <condition>Leptomeningeal Disease</condition>
  <arm_group>
    <arm_group_label>Avelumab and Whole Brain Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avelumab 800 mg intravenously (IV) and 3000 centriGray units (cGy) Whole Brain Radiotherapy once every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Patients will be given 800 mg Avelumab as a one hour intravenous infusion once every 2 weeks.</description>
    <arm_group_label>Avelumab and Whole Brain Radiotherapy</arm_group_label>
    <other_name>Bavencio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole Brain Radiotherapy</intervention_name>
    <description>Patients will be given 3000 cGy Whole Brain Radiotherapy once every 2 weeks</description>
    <arm_group_label>Avelumab and Whole Brain Radiotherapy</arm_group_label>
    <other_name>WBRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Histologically or cytologically confirmed diagnosis of any cancer except leukemia&#xD;
&#xD;
          -  2. Patients must have the presence of malignant cells in the CSF (CSF+) OR at least 2&#xD;
             of the 3 following features: 1) clinical signs and symptoms of LMDz 2) characteristic&#xD;
             radiographic abnormalities , and 3) &quot;suspicious&quot; CSF (Chamberlain 2017)&#xD;
&#xD;
          -  3. Patients must have an Eastern Cooperative Oncology Group performance scale of &lt; 3&#xD;
             OR Karnofsky Performance Status of &gt;50.&#xD;
&#xD;
          -  4. An interval of at least 2 weeks after the end of prior radiation therapy to the&#xD;
             brain (e.g., stereotactic radiosurgery or other-WBRT is excluded)&#xD;
&#xD;
          -  5. An interval of at least 4 weeks following any surgical resection of brain lesions&#xD;
             prior to treatment&#xD;
&#xD;
          -  6. Be &gt; 18 years of age on the day of signing consent&#xD;
&#xD;
          -  7. Demonstrate adequate organ function as defined in Table 2. All screening labs&#xD;
             should be performed with 14 days of treatment initiation&#xD;
&#xD;
          -  8. Resting baseline O2 saturation by pulse oximetry of &gt; 92% at rest&#xD;
&#xD;
          -  9. Patients must have recovered from the toxic effects of prior therapies (&lt; Grade 1)&#xD;
&#xD;
          -  10. Provision of signed and dated informed consent form&#xD;
&#xD;
          -  11. Life expectancy of &gt; 8 weeks&#xD;
&#xD;
          -  12. Pregnancy test: negative serum or urine pregnancy test at screening for women of&#xD;
             childbearing potential.&#xD;
&#xD;
          -  13. Contraception: Highly effective contraception for both male and female subjects&#xD;
             throughout the study and for at least 30 days after last Avelumab treatment&#xD;
             administration, if the risk of conception exists.&#xD;
&#xD;
          -  14. If the disease has progressed on current treatment in the CNS prior to consent,&#xD;
             patients may continue Her 2 directed antibody treatment (trastuzumab and pertuzumab),&#xD;
             aromatase inhibitor or tamoxifen while on the study; patients with triple negative&#xD;
             breast cancer may continue capecitabine, eribulin or paclitaxel while on the study per&#xD;
             PI discretion.&#xD;
&#xD;
          -  15. Adequate Organ Function as defined per protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Receiving other treatments specifically administered to treat LMDz or antibody&#xD;
             based therapies within the last 4 weeks. However, patients receiving concomitant&#xD;
             non-cytotoxic therapy (hormonal or cytostatic therapy) to control systemic disease or&#xD;
             bulk CNS disease will be eligible, provided the therapy is not a phase I agent, an&#xD;
             agent which significantly penetrates the CSF (e.g., high-dose methotrexate, thiotepa,&#xD;
             or high-dose ara-C), or an agent known to have serious unpredictable CNS side effects&#xD;
             Except as listed in Inclusion Criteria #15 (above). Careful documentation of&#xD;
             concurrently administered systemic drugs is required&#xD;
&#xD;
          -  2. Patients with a ventriculoperitoneal or ventriculoatrial shunt must have an on/off&#xD;
             device in their shunt systems to be eligible for the study. Patients must be able to&#xD;
             tolerate shunt closure for ~4 hours without development of clinical signs of increased&#xD;
             intracranial pressure. Patients unable to tolerate shunt closure for ~4 hours will not&#xD;
             be eligible for the study&#xD;
&#xD;
          -  3. Unable or unwilling to have a contrast-enhanced brain MRI&#xD;
&#xD;
          -  4. Currently participating in or having participated in a study of an investigational&#xD;
             agent or device &lt; 4 weeks prior to the first dose of study treatment&#xD;
&#xD;
          -  5. Patients on steroid therapy unless &lt; 2 mg/day dexamethasone equivalents&#xD;
&#xD;
          -  6. Prior chemotherapy or targeted small molecule therapy except as listed in Inclusion&#xD;
             Criteria #15 and Exclusion #1(above) within 4 weeks prior to study Day 1 or&#xD;
             nonrecovery (i.e., &lt; Grade 1 or at baseline) from adverse events (AEs) due to agents&#xD;
             administered &gt; 4 weeks earlier&#xD;
&#xD;
          -  7. Known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin, or in situ cervical cancer that has undergone potentially curative therapy&#xD;
&#xD;
          -  8. Has an active autoimmune disease requiring systemic treatment within the past 3&#xD;
             months (i.e. with use of disease modifying agents, corticosteroids or&#xD;
             immunosuppressive agents) or has a diagnosis of immunodeficiency. Subjects with&#xD;
             vitiligo or resolved childhood asthma/atopy would be an exception to this rule.&#xD;
             Subjects that require intermittent use of bronchodilators or local steroid injections&#xD;
             would not be excluded from the study. Subjects with hypothyroidism stable on hormone&#xD;
             replacement or Sjorgen's syndrome will not be excluded from the study. Replacement&#xD;
             therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy&#xD;
             for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic&#xD;
             treatment.&#xD;
&#xD;
          -  9. Has evidence of active, non-infectious pneumonitis&#xD;
&#xD;
          -  10. Has an active infection requiring systemic therapy&#xD;
&#xD;
          -  11. Had major surgical procedure, open biopsy, or significant traumatic injury within&#xD;
             28 days prior to day 1 of treatment on study. Ommaya placement is allowed&#xD;
&#xD;
          -  12. Requires escalating or chronic supraphysiologic doses of corticosteroids (&gt; 10&#xD;
             mg/day prednisone equivalents)&#xD;
&#xD;
          -  13. Has a history of current evidence of any condition, therapy, or laboratory&#xD;
             abnormality that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator&#xD;
&#xD;
          -  14. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial&#xD;
&#xD;
          -  15. Is pregnant or breastfeeding, or expecting to conceive or father children within&#xD;
             the projected duration of the trial, starting with the pre-screening or screening&#xD;
             visit through 90 days after the last dose of trial treatment&#xD;
&#xD;
          -  16. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137,&#xD;
             or anti- Cytotoxic T-lymphocyte-associated antigen-4 (cTLA-4) antibody (including&#xD;
             ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation&#xD;
             or checkpoint pathways) within 6 months before the beginning of study treatment&#xD;
&#xD;
          -  17. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1, 2 antibodies)&#xD;
&#xD;
          -  18. Any test for hepatitis B (HBV) or hepatitis C virus (HCV) indicating acute or&#xD;
             chronic infection&#xD;
&#xD;
          -  19. Has received a live vaccine within 30 days prior to the first dose of trial&#xD;
             treatment&#xD;
&#xD;
          -  20. Prior administration of WBRT&#xD;
&#xD;
          -  21. Known symptomatic brain metastases requiring steroids. Patients with previously&#xD;
             diagnosed brain metastases are eligible if they have completed their treatment and&#xD;
             have recovered from the acute effects of radiation therapy or surgery prior to study&#xD;
             treatment, have discontinued corticosteroid treatment for these metastases for at&#xD;
             least 4 weeks and are neurologically stable. Short courses of corticosteroids are&#xD;
             permitted if these were started for leptomeningeal disease and can be tapered down to&#xD;
             &lt; 2 mg/day of dexamethasone equivalents and patients remain stable for 3 days prior to&#xD;
             study treatment&#xD;
&#xD;
          -  22. Known severe hypersensitivity reactions to monoclonal antibodies (Grade &gt; 3) or&#xD;
             any known history of anaphylaxis&#xD;
&#xD;
          -  23. ORGAN TRANSPLANTATION: Prior organ transplantation including allogenic stem-cell&#xD;
             transplantation&#xD;
&#xD;
          -  24. CARDIOVASCULAR DISEASE: Clinically significant (i.e., active) cardiovascular&#xD;
             disease: cerebral vascular accident/stroke (&lt; 6 months prior to enrollment),&#xD;
             myocardial infarction (&lt; 6 months prior to enrollment), unstable angina, congestive&#xD;
             heart failure (&gt; New York Heart Association Classification Class II), or serious&#xD;
             cardiac arrhythmia requiring medication&#xD;
&#xD;
          -  25. OTHER PERSISTING TOXICITIES: &quot;Persisting toxicity related to prior therapy (NCI&#xD;
             CTCAE v.5.0 Grade &gt; 1); however, alopecia, sensory neuropathy Grade &lt; 2, or other&#xD;
             Grade &lt; 2 not constituting a safety risk based on investigator's judgment are&#xD;
             acceptable&#xD;
&#xD;
          -  26. Other severe acute or chronic medical conditions, including immune colitis,&#xD;
             inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric&#xD;
             conditions including recent (within the past year) or active suicidal ideation or&#xD;
             behavior; or laboratory abnormalities that may increase the risk associated with study&#xD;
             participation or study treatment administration or may interfere with the&#xD;
             interpretation of study results and, in the judgment of the investigator, would make&#xD;
             the patient inappropriate for entry into this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Forsyth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Drury-Sibiga</last_name>
      <phone>813-745-5689</phone>
      <email>Ali.Drury-Sibiga@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Peter Forsyth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Solmaz Sahebjam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yolanda Pina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikhil Khushlani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inna Smalley, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kerian Smalley, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://moffitt.org/clinical-trials-research/clinical-trials/</url>
    <description>Moffitt Cancer Center Clinical Trials Website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Whole Brain Radiotherapy</keyword>
  <keyword>meningeal</keyword>
  <keyword>LMDz</keyword>
  <keyword>brain metastases</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Meningeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

